E.C. tablet Pantoprazole 20, 40 mg

Generic Name of ProductBrand NameDosage Form StrengthPharmacologic GroupTherapeutic GroupUnit Per Pack
Pantoprazole-Tablet/ vial40mg+20mg/40mgProton pump inhibitorGastrointestinal agents30 / 12

Indications And Usage
  1. Pantoprazole is indicated for use in Adults and adolescents 12 years of age and above for
  2. Reflux oesophagitis.
  3. Pantoprazole is indicated for use in Adults for
  4. Eradication of Helicobacter pylori (H. pylori) in combination with appropriate antibiotic therapy in patients with H. pylori associated ulcers.
  5. Gastric and duodenal ulcer.

Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions.


Adults and adolescents 12 years of age and above


Reflux oesophagitis

One tablet of Pantoprazole per day. In individual cases the dose may be doubled (increase to 2 tablets Pantoprazole daily )   . especially when there has been no response to other treatme_  A 4-week period is usually required for the treatment of reflux oesophagitis If this is not sufficient, healing will usually be achieved within a further 4 weeks.

Eradication of H. pylori in combination with two appropriate antibiotics :

In H. pylori positive patients with gastric and duodenal ulcers, eradication of the germ by a combination therapy should be achieved

 Considerations should be given to official local guidance (e.g. national recommendations)

regarding bacterial resistance and the appropriate use and prescription of antibacterial agents. Depending upon the resistance pattern, the following combinations can be recommended for the eradication of H. pylori :

  1. a) twice daily one tablet Pantoprazole


+ twice daily 1000 mg amoxicillin


+ twice daily 500 mg clarithromycin


  1. b) twice daily one tablet Pantoprazole


+ twice daily 400 - 500 mg metronidazole (or 500 mg tinidazole)


+ twice daily 250 - 500 mg clarithromycin


  1. c) twice daily one tablet Pantoprazole


+ twice daily 1000 mg amoxicillin


+ twice daily 400 - 500 mg metronidazole (or 500 mg tinidazole)


Hypersensitivity to the active substance, substituted benzimidazoles or to any of the excipients.


Gastric malignancy

Symptomatic response to pantoprazole may mask the symptoms of gastric malignancy and may delay diagnosis.In the presence of any alarm symptom (e. g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis, anaemia or melaena) and when gastric ulcer is suspected or present, malignancy should be excluded.

Adverse Reactions

Dizziness, Visual impairment

Pregnancy and lactation


A moderate amount of data on pregnant women (between 300-1000 pregnancy outcomes) indicate no malformative or feto/ neonatal toxicity of Pantoprazole. As a precautionary measure, it is preferable to avoid the use of pantoprazole during pregnancy.



Animal studies have shown excretion of pantoprazole in breast milk. There is insufficient information on the excretion of pantoprazole in human milk but excretion into human milk has been reported. A risk to the newborns/infants cannot be excluded. Therefore a decision on whether to discontinue breast-feeding or to discontinue/abstain from Pantoprazole therapy taking into account the benefit of breast- feeding to the child and the benefit of Pantoprazole therapy to women

Renal and liver Impairment

Hepatic Impairment

In patients with severe liver impairment, the liver enzymes should be monitored regularly during treatment with pantoprazole, particularly on long-term use. In the case of a rise of the liver enzymes, the treatment should be discontinued

Patients with renal Impairment


No dose adjustment is necessary in patients with impaired renal function. Pantoprazole must not be used in combination treatment for eradication of H. pylori in patients with impaired renal function since currently no data are available on the efficacy and safety of Pantoprazole in combination treatment for these patients

Laboratory Tests